HER2-positive Stage IV breast cancer: T-DM1 extravasation wound healed after multidisciplinary care

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER 90% positive; PR 70% positive; HER2 IHC 3+

Metastatic Site: pelvis

As of October 2025, the T-DM1 extravasation wound had almost fully healed within about 4 weeks, and the patient continued adjuvant T-DM1 through a port; longer cancer-control status was not described.

PubMed CentralRead more →

HER2-positive invasive lobular breast cancer in a transgender man: disease-free after multimodality care

Patient Info: Anonymized, transgender man, 70+ | Stage III

Biomarkers: HER2-positive invasive lobular breast cancer, ER/PR negative

Nearly 2 years after diagnosis, he remained disease-free while continuing survivorship care and counseling after discontinuing testosterone therapy.

PubMed CentralRead more →

Synchronous triple-negative breast cancer and rectal adenocarcinoma complicated by hepatitis B reactivation

Patient Info: Anonymized, Female, 50s

Biomarkers: Triple-negative breast cancer with pathogenic BRCA1 mutation; hepatitis B reactivation occurred during treatment.

At 3-year follow-up, she remained healthy and disease-free after treatment for synchronous triple-negative breast cancer and mid-rectal adenocarcinoma, with hepatitis B reactivation controlled on entecavir.

PubMed CentralRead more →

HER2-positive node-positive breast cancer: mastectomy and adjuvant TCbHP

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: HER2-positive breast cancer with ER/PR positivity, PD-L1 CPS 25

Adjuvant TCbHP was initiated after surgery, the first cycle was tolerated with supportive care, and regular monitoring was ongoing without evidence of distant recurrence or metastasis reported.

PubMed CentralRead more →

HER2-positive breast cancer with brain, skin, and lymph-node metastases responding to dual-targeted therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: HER2-positive breast cancer. Initial tumor was ER/PR negative with Ki-67 30%; skin metastasis had Ki-67 70%.

Metastatic Site: brain, left cervical lymph nodes, skin of left chest…

After 1 cycle of inetetamab trastuzumab, pyrotinib, and capecitabine, skin metastases regressed, CEA and CA125 decreased, brain lesions shrank, and the largest lesion decreased by about 46%, meeting partial response; disease remained stable as of September 2024.

PubMed CentralRead more →

Stage IV HER2-Positive Breast Cancer: Elissa's Patient Story

Patient Info: Elissa, Female, Under 40 | Stage IV

Biomarkers: HER2-positive; no hereditary mutation reported

Metastatic Site: lymph nodes, liver, spine

Elissa had Stage IV HER2-positive metastatic breast cancer with an early strong response to systemic therapy, but she described the disease as long-term and not curative. As of July 2025, she had lived with metastatic breast cancer for about 4 years and had received roughly 5 lines of treatment.

The Patient StoryRead more →

Stage III Triple-Negative Breast Cancer: Lynn's Survivor Story

Patient Info: Lynn Leiro, Female, Under 40 | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative

Lynn achieved complete response after breast cancer treatment and remission from therapy-related acute lymphocytic leukemia after CAR T cell therapy and bone marrow transplant; as of July 2025, nearly 1 year post-transplant, she was doing better and getting stronger.

City of HopeRead more →

Stage IIIB triple-negative breast cancer: complete response after LVAD-supported neoadjuvant immunotherapy

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; Ki-67 95%; nuclear grade 3, triple negative

As of July 2025, breast cancer remained in remission 2.5 years after mastectomy, after neoadjuvant paclitaxel/carboplatin/pembrolizumab, surgery, radiation, and 1 year of adjuvant pembrolizumab.

PubMed CentralRead more →

HER2-Positive Pleomorphic Lobular Breast Cancer in a 43-Year-Old Woman

Patient Info: Anonymized, Female, 40s

Biomarkers: HER2-positive, ER-negative, PR-negative

Postoperative adjuvant treatment continued with HER2-targeted therapy after chemotherapy and radiation.

PubMed CentralRead more →

Severe Melioidosis During Chemotherapy for Metastatic Breast Cancer

Patient Info: Anonymized, Female, 50s | Stage IV

A 58-year-old woman with metastatic breast cancer developed life-threatening melioidosis and severe low blood counts after her sixth chemotherapy cycle, requiring intensive infection treatment.

PubMed CentralRead more →

Metaplastic triple-negative breast cancer: near-complete response to taxane/carboplatin before surgery

Patient Info: Anonymized, Female, Under 40 | Stage Metastatic/Advanced

Biomarkers: ER-negative; PR-negative; HER2-negative; CA 15-3 elevated, triple negative

As of April 2025, imaging after taxane/carboplatin showed a near-complete morpho-metabolic response in the right breast and major reduction of axillary nodal disease, followed by surgery and adjuvant chemotherapy/radiotherapy.

PubMed CentralRead more →

Lung inflammation from pembrolizumab immunotherapy returned months after stopping treatment

Patient Info: Anonymized, Female, 70+

Biomarkers: Estrogen receptor-negative; progesterone receptor-negative; HER2-negative

Surgery confirmed a pathologic complete response, and she remained in breast-cancer remission during routine follow-up after treatment for recurrent pembrolizumab-related pneumonitis.

PubMed CentralRead more →

HER2-Positive Breast Cancer Treated After Chemotherapy-Related Hemorrhagic Cystitis

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-negative, PR-negative, HER2-positive

Under surveillance with no evidence of breast-cancer recurrence for 2 years.

PubMed CentralRead more →

HER2-Positive Invasive Ductal Breast Cancer Treated After Chemotherapy-Related Hemorrhagic Cystitis

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive, PR-positive, HER2-positive

Under surveillance for 2 years with no signs of malignancy.

PubMed CentralRead more →

Stage II Triple-Negative Breast Cancer With Severe Myelitis During Pembrolizumab Treatment

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER-negative, PR-negative, HER2-negative, germline PALB2 variation

Imaging showed a complete tumor response before surgery, and surgery 6 months later found no residual breast cancer or involved sentinel nodes.

PubMed CentralRead more →

Facing Triple-Negative Breast Cancer: Chance’s Story

Patient Info: Chance, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

As of February 2025, Chance described follow-up after Stage II BRCA1-associated triple-negative breast cancer and stated that she did not currently have cancer, while continuing close surveillance.

The Patient StoryRead more →

Stage III Triple-Negative Breast Cancer: Kelly's Survivor Story

Patient Info: Kelly, Female, Under 40 | Stage III

Biomarkers: Triple-negative breast cancer; no inherited cancer gene mutation found.

As of February 2025, Kelly identified as a Stage IIIC triple-negative breast cancer survivor after neoadjuvant chemotherapy, double mastectomy with reconstruction, and radiation, and was using her experience to support others through TNBC Thrivers.

The Patient StoryRead more →

Stage IIIC triple-negative breast cancer with pembrolizumab-related HLH/DIC and pathologic complete response

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative/HR-negative breast cancer with germline BRCA1 pathogenic mutation. HLH/DIC episode had high IL-6

Surgery confirmed ypT0ypN0 pathologic complete response after neoadjuvant carboplatin, paclitaxel, and pembrolizumab, and she remained recurrence-free while being monitored without additional cancer-directed treatment.

PubMed CentralRead more →

Metastatic breast cancer with receptor evolution: sequential endocrine, immunotherapy, CDK4/6, and antibody-drug conjugate treatment

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Markers changed over time: initial tumor ER-positive/HER2-negative; local recurrence triple-negative/HER2-low; pleural fluid ER-negative.

Metastatic Site: mediastinal lymph nodes, pleura; pulmonary nodules…

More than 7 years after diagnosis, she remained on sequential systemic therapy for metastatic breast cancer, with at least a partial response 3 months after starting sacituzumab govitecan for presumed triple-negative pleural disease.

PubMed CentralRead more →

Stage III HER2-Positive Breast Cancer Complicated by Systemic Sclerosis During Treatment

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: HER2-positive

At 3-month follow-up after anticancer treatment was stopped, no breast-cancer recurrence or metastasis was detected.

PubMed CentralRead more →

Stage III HER2-Positive Occult Breast Cancer With a Complete Response to Treatment

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: HER2-positive

Surgery after neoadjuvant treatment found no residual tumor in the breast or 20 examined lymph nodes, indicating a complete pathologic response; HER2-targeted therapy continued afterward.

PubMed CentralRead more →

Stage 4 breast cancer: ongoing treatment with multi-line chemotherapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Initial tumor: hormone receptor-negative; HER2 2+. 2011 recurrence: ER 10%; PR 70%; HER2 2+.

Metastatic Site: pleura/pleural effusion; lung

Metastatic breast cancer with malignant pleural effusion achieved complete response after chemotherapy and long-term endocrine therapy; PET-CT in October 2023 still showed complete response, with ongoing cardiac and bone-health management.

PubMed CentralRead more →

Triple-Negative Pleomorphic Lobular Breast Cancer in a BRCA1 Carrier

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative, BRCA1 pathogenic mutation

Surgery after neoadjuvant treatment showed a complete pathologic response with no cancer in the 2 sampled sentinel lymph nodes.

PubMed CentralRead more →

Stage 3 breast cancer: pathologic complete response to neoadjuvant chemotherapy

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-positive, PR-negative, HER2-negative breast cancer with very high Ki-67. MammaPrint high-risk/basal type; hereditary testing negative.

Free of recurrence at last follow-up after neoadjuvant pembrolizumab plus chemotherapy, breast-conserving surgery with RCB-0/pathologic complete response, adjuvant radiation, and adjuvant pembrolizumab.

PubMed CentralRead more →